ModivCare upgraded to Outperform from Market Perform at Barrington

Barrington upgraded ModivCare to Outperform from Market Perform with a $35 price target. While the balance sheet remains “quite leveraged” and operational risks remain, the firm believe that the business is likely to deliver better results in the second half and return to “a much more normalized operational backdrop” in FY25, the analyst tells investors.